logo
Share SHARE
FONT-SIZE Plus   Neg

Optimer Pharma Names Hank McKinnell Chairman - Quick Facts

Optimer Pharmaceuticals (OPTR) announced that its board of directors has appointed Hank McKinnell as its new chairman. The company added that Kurt Hartman, who currently serves as General Counsel, chief compliance officer and senior vice president, has been appointed acting chief financial officer, or CFO, and that a search for a permanent CFO has commenced.

The company noted that the appointments were made after its board of directors removed Dr. Michael Chang as chairman and terminated John Prunty, CFO, and Dr. Youe-Kong Shue, vice president. The Board, excluding Chang, unanimously approved the personnel changes. Chang remains as a director of the company, but the Board has requested his resignation.

According to Optimer Pharma, the changes are not expected to materially impact its revenues or operations, including the commercialization and launch of DIFICID, but were related to certain lapses in corporate governance practices and the company's relationship with Optimer Biotechnology, Inc., its 43%-owned independent, Taiwanese-based affiliate.

Separately, Optimer Pharma stated that based upon preliminary results, it expects to report gross revenues of around $16.45 million for the first quarter of 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With a view to promoting the all new Prius brand in U.S., Toyota has launched a lighthearted commercial. It highlights the reinvention of the hybrid technology. The advertisement was aired during the first half of Super Bowl 50 and was well received in social media. Cisco Systems Inc. (CSCO), the world's largest computer networking gear maker, is accelerating its ability to deliver on growth opportunities, aggressively driving its cloud business, and delivering continued strength in its deferred product revenue, as we sell more of its portfolio in software and cloud models. In fiscal 2016, the company sees a 25% increase in major new product introductions. Sanofi (SNYNF, SNY) reported that its fourth-quarter net income attributable to equity holders decreased to 334 million euros from 1.34 billion euros, last year. Earnings per share was 0.26 euros compared to 1.02 euros. Earnings per share excluding the held for exchange Animal Health Business was 0.41...
comments powered by Disqus
Follow RTT